{"entity":{"id":"nct04644289","kind":"trial","name":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","aka":[],"tldr":"A phase 2 trial of Olaparib, Durvalumab in ovarian cancer, run by AGO Research GmbH, now recruiting.","summary":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC is a phase 2 interventional study registered as NCT04644289 by AGO Research GmbH, with 60 participants planned, started 2022-05-05 and due to reach its primary completion in 2028-01. Interventions recorded: olaparib, durvalumab. Conditions listed: Epithelial Ovarian Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04644289","url":"https://clinicaltrials.gov/study/NCT04644289"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["olaparib","durvalumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04644289","phase":"2","setting":"Window-of-opportunity Proof-of-concept, Non-randomized, Open-label Phase II Trial of Olaparib Given Alone (Cohort A) or in Combination With Durvalumab (Cohort B) Prior to Primary Debulking Surgery in Histologically Proven High-grade Epithelial Ovarian Cancer (EOC)","sponsor":"AGO Research GmbH","enrolled":60,"outcomes":[]},"route":"/trials/nct04644289/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}]}}